These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20346894)

  • 1. The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statement.
    Cheung AK; Chen MH; Moran BJ; Braccioforte MH; Dosoretz DE; Salenius S; Katin M; Ross R; D'Amico AV
    Brachytherapy; 2010; 9(2):145-50. PubMed ID: 20346894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis.
    Kalakota K; Rakhno E; Pelizzari CA; Jani AB; Liauw SL
    Brachytherapy; 2010; 9(2):131-6. PubMed ID: 19853533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practice.
    Hattangadi JA; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
    Brachytherapy; 2011; 10(5):369-75. PubMed ID: 21349778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate brachytherapy: a descriptive analysis from CaPSURE.
    Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
    Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer.
    Zelefsky MJ; Moughan J; Owen J; Zietman AL; Roach M; Hanks GE
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1053-61. PubMed ID: 15234039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
    Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
    J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
    Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
    Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience.
    Sylvester JE; Grimm PD; Blasko JC; Millar J; Orio PF; Skoglund S; Galbreath RW; Merrick G
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):57-64. PubMed ID: 17084544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States.
    Lee WR; Moughan J; Owen JB; Zelefsky MJ
    Cancer; 2003 Nov; 98(9):1987-94. PubMed ID: 14584083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.
    Dosoretz AM; Chen MH; Salenius SA; Ross RH; Dosoretz DE; Katin MJ; Mantz C; Nakfoor BM; D'Amico AV
    Cancer; 2010 Feb; 116(4):837-42. PubMed ID: 20052734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology.
    Pistis F; Guedea F; Pera J; Gutierrez C; Ventura M; Polo A; Martinez E; Boladeras A; Ferrer F; Gabriele P; Linares L
    Brachytherapy; 2010; 9(1):15-22. PubMed ID: 19734106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.